SEER Inquiry System - Question 20160077 Details

System Guide

Back to Search Results

SEER Inquiry System - Report

Produced: 11/03/2025 8:00 PM

Question 20160077

Export CSV Export PDF Print

Add to Report

Inquiry Details

References:

SEER*Rx

Question:

First course treatment/Immunotherapy--Prostate: Is XGEVA, given for bone mets from prostate cancer, abstracted as immunotherapy, or is it an ancillary drug and not recorded?

Discussion:

Answer:

Do not record XGEVA when given for bone mets from prostate cancer. See SEER*Rx for more information.

Cancer Site Category:

Prostate

Data Item Category:

First course treatment, Immunotherapy

Other Category:

N/A

Year:

2016